Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History KZIA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics KZIA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield 0.10 %
Consecutive Years 0
Forward Annual Dividend 0.0067 USD
Consistent Years 0
Dividend CAGR 3Y
Continuous Dividends 0
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date 28.01.2013

Kazia Therapeutics Ltd ADR

KZIA
Current price
6.77 USD -2.28 USD (-25.19%)
Last closed 9.15 USD
ISIN US48669G1058
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 12 440 522 USD
Yield for 12 month -88.02 %
1Y
3Y
5Y
10Y
15Y
KZIA
21.11.2021 - 28.11.2021

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Address: Three International Towers, Sydney, NSW, Australia, 2000

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

14.85 USD

P/E ratio

Dividend Yield

Financials KZIA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures KZIA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 493 045 USD

Last Year

+359 USD

Current Quarter

+1 604 956 USD

Last Quarter

+3 USD

Current Year

+1 493 045 USD

Last Year

+359 USD

Current Quarter

+1 604 956 USD

Last Quarter

+3 USD
EBITDA -27 077 976 USD
Operating Margin TTM -42 029.54 %
Price to Earnings
Return On Assets TTM -85.55 %
PEG Ratio
Return On Equity TTM -3 891.64 %
Wall Street Target Price 14.85 USD
Revenue TTM 2 503 285 USD
Book Value -3.94 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 557 150.00 %
Dividend Yield
Gross Profit TTM 2 503 285 USD
Earnings per share -29.09 USD
Diluted Eps TTM -29.09 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation KZIA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.83
Price Sales TTM 4.84
Enterprise Value EBITDA -0.71
Price Book MRQ 3.09

Technical indicators KZIA

For 52 weeks

2.86 USD 79.00 USD
50 Day MA 4.45 USD
Shares Short Prior Month 19 992
200 Day MA 12.28 USD
Short Ratio 0.58
Shares Short 14 394
Short Percent 1.07 %